Skip to main content

Want a detailed portfolio tracker?

DMAAR
NASDAQ
$0.17

Drugs Made In America Acquisition Corp (DMAAR)

Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company targeting the revitalization of domestic pharmaceutical manufacturing to address pressing healthcare needs and supply chain vulnerabilities. Harnessing the expertise of a seasoned management team, DMAAR aims to identify and merge with established pharmaceutical players, positioning itself to leverage growth opportunities in an evolving market. By prioritizing resilience and self-sufficiency in American healthcare, DMAAR offers institutional investors a compelling opportunity for both substantial returns and a positive societal impact within the pharmaceutical sector.

This company is also listed under the following tickersDMAAU, DMAA.

Website: https://dmaacorp.com

Market Cap

$1.29M

P/E Ratio

0.19

Free Cash Flow Yield

-29.48%

Beta (5Y)

-0.55

Price Chart

Valuation
Market Cap$1.29M
P/E0.19
Profitability
EBITDA$6.66M
EPS$0.63
Financial Health
Free Cash Flow Yield-29.48%
Growth & Risk
Beta (5Y)-0.55
Sharpe Ratio0.29